#Switzerland #Heart Failure #Zug #Berlin Heals #C-MIC

Berlin Heals Holding AG Secures Funding for Heart Failure Treatment Research

Berlin Heals Holding AG, a Swiss medical technology startup, has successfully raised more than 7 million CHF in a recent funding round aimed at advancing its groundbreaking research into less invasive heart failure treatments. This funding will support crucial initial human trials and help prepare for a pivotal large-scale trial necessary for obtaining worldwide regulatory approvals and reimbursements.

The company's flagship product, the C-MIC (Cardiac Microcurrent), represents a significant innovation in the treatment of heart failure. This electronic device has already undergone successful testing in a pilot study involving patients and has completed recruitment for a multicentric, randomized clinical trial in pursuit of CE certification. As testament to its potential, the C-MIC utilizes a constant microcurrent to improve cardiac function, providing patients with a hope for better health outcomes.

John Brumfield, CEO of Berlin Heals Holding AG, expressed gratitude toward both their internal and new investors, stating that their ongoing support is crucial in their mission to combat heart disease. The CEO also highlighted the strong potential revealed by early clinical results, creating excitement as they prepare to share findings from the new randomized trial this coming year.

Recent presentations at major conferences have showcased the promising durable long-term results of initial studies on dilated cardiomyopathy. Berlin Heals Holding AG aims to continue this momentum by evaluating new implantation methods that are notably less invasive. Felix Baader, Chairman of the Board, shared his firsthand experiences with patients, which invigorated the team's commitment to enhancing patients' quality of life through their innovative device.

Equipped with this new funding, Berlin Heals Holding AG is poised to progress significantly in its development of the C-MIC and is eager to lay the groundwork for the CE authorization application of its first-generation device. The firm is enthusiastic about its capacity to transform the landscape of heart failure treatment.

Founded in 2014, Berlin Heals Holding AG is a publicly-traded entity in Switzerland, driven by a passion for innovating patient care through technology. As they carve out their niche in medical technology, the company remains focused on addressing the pressing global needs of those afflicted with heart diseases, ensuring their innovations continue to resonate across the healthcare landscape.

In this evolving journey towards improving heart health, Berlin Heals Holding AG remains steadfast in its commitment to patient wellbeing, innovation, and achieving groundbreaking results in cardiovascular care. As we await more updates about their clinical trials and regulatory achievements, the future looks bright for both the company and the patients they serve.